Cancer Management Guidelines

Long Term Follow-Up Post Allogeneic HSCT
Publications

Updated: October 2010

  1. Michelle L. Griffith et al. Dyslipidaemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010; 116:1197-1204.
    PDF icon Griffith M 2010 Blood
  2. J. Douglas Rizzo et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113; 1175-1183.
    PDF icon Rizzo JD 2009 Blood
  3. Andre Tichelli et al. Late Pulmonary, Cardiovascular, and Renal Complications after Hematopoietic Stem Cell Transplantation and Recommended Screening Practices. Hematology (ASH education book) 2008: 125-133.
    PDF icon Tichelli A 2008 Hematology
  4. Andre Tichelli et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93(8): 1203-1210.
    PDF icon Tichelli A 2008 Haematologica
  5. JD Rizzo et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow transplant research, and the American society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplantation 2006; 37:249-261.
    PDF icon Rizzo JD 2006 Bone Marrow Transplantation
  6. Gerard Socie et al. Nonmalignant late effects after stem cell transplantation. Blood 2003; 101: 3373-85.
    PDF icon Gerard S 2003 Blood

 

The information contained in these guidelines is a statement of consensus of Leukemia/BMT Program of BC professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these guidelines and documents is at your own risk and is subject to the Leukemia/BMT Program of BC’s terms of use available at Terms of Use.

Privacy Statement
|
Terms of Use
|
hemwebcontact@bccancer.bc.ca
| visitor ip address: 38.107.179.243
© 2011 Leukemia/BMT Program of BC